Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025MedicineOpen Access

Therapeutic efficacy of dienogest combined with GnRH agonist in adenomyosis and associated obstetric risk factors: A meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYan WangXWXiye WangLZLe-Yi Zhang

Discussion

Loading...

Member takes

Implication

Meta-analysis shows therapeutic efficacy of dienogest plus GnRH agonist in adenomyosis, indicating reduced preterm birth risk.

Key Points

  • Combination of dienogest and GnRH agonist significantly improves treatment outcomes for adenomyosis, enhancing therapeutic efficacy.
  • In a meta-analysis of 5 studies involving 520 patients, key metrics such as hemoglobin levels and uterine volume were positively impacted.
  • The analysis indicates that adenomyosis is associated with increased obstetric risks, particularly preterm birth and cesarean section.
  • Findings suggest that combining dienogest with GnRH agonists may improve overall outcomes for women with adenomyosis during treatment.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/6930dc9eea1aef094cca2d63https://doi.org/10.1097/md.0000000000045907
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adenomyosis and adverse perinatal outcomes: increased risk of second trimester miscarriage, preeclampsia, and placental malposition2017 · 144 citations
  2. 2Uterine wall thickness at the second trimester can predict subsequent preterm delivery in pregnancies with adenomyosis2019 · 19 citations
  3. 3Hormonal treatments for endometriosis: The endocrine background2021 · 320 citations